COVID-19, HHV6 and MOG antibody: A perfect storm
- 11 February 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Neuroimmunology
- Vol. 353, 577521
- https://doi.org/10.1016/j.jneuroim.2021.577521
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 25 references indexed in Scilit:
- The clinics of HHV ‐6 infection in COVID ‐19 pandemic: Pityriasis rosea and Kawasaki diseaseDermatologic Therapy, 2020
- Neurological Implications of COVID-19 InfectionsNeurocritical Care, 2020
- Acute transverse myelitis after COVID-19 pneumoniaZeitschrift für Neurologie, 2020
- Hematological findings and complications of COVID‐19American Journal of Hematology, 2020
- Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, ChinaInternational Journal of Infectious Diseases, 2020
- Current understanding of human herpesvirus 6 (HHV-6) chromosomal integrationAntiviral Research, 2020
- Clinical characteristics of human herpesvirus-6 myelitis after allogeneic hematopoietic stem cell transplantation and its favorable outcome by early interventionBone Marrow Transplantation, 2019
- Postinfectious Anti–Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and MyelitisJournal of Child Neurology, 2017
- Idiopathic transverse myelitisNeurology, 2007
- Human herpesvirus 6 (HHV‐6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV‐6 DNAJournal of Medical Virology, 2004